ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Temporal trends, patient characteristics and hospital volume outcomes after transcoronary ablation of septal hypertrophy and septal myectomy for treatment of obstructive hypertrophic cardiomyopathy.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Forward Dynamics: Modern Insights into Mitral Systolic Anterior Motion.Journal of cardiovascular development and disease · 2026Review
- Authors' response: septal reduction therapy for obstructive hypertrophic cardiomyopathy.European heart journal open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic obstructive cardiomyopathy (HOCM) is a hereditary cardiac disease associated with poor prognosis. Data on septal reduction therapy (SRT), including transcoronary ablation of septal hypertrophy (TASH) and surgical myectomy (SM), are limited. We aimed to evaluate temporal trends, patient characteristics, in-hospital outcomes, and the influence of institutional procedural volumes in a nationwide cohort.
methodsWe used nationwide administrative data from the German Federal Bureau of Statistics to identify HOCM patients undergoing TASH or SM between 2006 and 2019. Primary outcomes were in-hospital mortality and pacemaker implantation. Multivariable logistic regression assessed associations with institutional procedure volume.
resultsAmong 8,514 SRT procedures, 5,293 (62.2%) were TASH and 3,221 (37.8%) SM. Annual volumes increased for both procedures between 2006 and 2019. SM patients were older (67.4 vs. 60.2 years), more often male, and had a higher comorbidity burden. Of all centers, 49.3% performed ≤ 20 SM per year, and 76.3% performed ≤ 20 TASH per year. Mitral surgery occurred in 36.1% of SM cases. In-hospital mortality was higher for SM than TASH (6.9% vs. 0.8%), while pacemaker implantation was more frequent with TASH (19.3% vs. 13.1%). Risk of in-hospital mortality after SM was higher in low-volume centers than in large centers (adjusted odds ratio 2.64; 95% confidence interval, 1.49-4.66).
conclusionSM was performed in older, more comorbid patiens and frequently included concomitant valve surgery. Higher in-hospital mortality at low-volume centers may partially reflect surgical complexity or case mix rather than volume alone. Our findings underscore the need for individualized referral strategies to experienced centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.